FASENRA
Benralizumab
- Strength
- 30 mg/mL
- Form
- Injection, Solution
- Class
- Interleukin-5 Receptor alpha-directed C…
AstraZeneca Pharmaceuticals LP
Not stocked by us — reference only
Benralizumab
Listed by AstraZeneca Pharmaceuticals LP
| Dosage form | Injection, Solution |
|---|---|
| Route | Subcutaneous |
| Drug class | Interleukin-5 Receptor alpha-directed Cytolytic Antibody |
| Approval route | BLA — biologic licence |
| NDC code | 0310-1745 |
| FDA application | BLA761070 |
| RxNorm concept | 1989104 |
| Package sizes listed | 2 |
| Marketed since | April 2024 |
Same active ingredient, different manufacturer, strength or form. Products matching on both ingredient and strength are usually interchangeable — but confirm before switching, especially with modified-release forms.
Benralizumab
AstraZeneca Pharmaceuticals LP
Not stocked by us — reference only
Benralizumab
AstraZeneca Pharmaceuticals LP
Not stocked by us — reference only
Information only, not medical advice. Nothing on this page indicates that a medication is safe or suitable for you. Speak to a prescriber or pharmacist before starting, stopping or switching any medicine.
Please don't share card details in chat.